Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Invasive Dental Treatment and Risk for a First Myocardial Infarction.

Journal of dental research·2018
Same author

Severe Periodontitis Is Associated with Myocardial Infarction in Females.

Journal of dental research·2018
Same author

Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: A nationwide study.

European journal of preventive cardiology·2017
Same author

The Swedish CArdioPulmonary BioImage Study: objectives and design.

Journal of internal medicine·2015
Same author

The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.

Journal of internal medicine·2013
Same author

ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data.

Journal of human hypertension·2013

相关实验视频

Updated: Jul 14, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

入院时的糖代谢状态:传统治疗糖尿病和急性心肌梗塞患者死亡的重要风险标志:糖尿病和胰岛素葡萄糖输液在急性心肌梗塞 (DIGAMI) 研究的长期结果.

K Malmberg1, A Norhammar, H Wedel

  • 1Department of Cardiology, Karolinska Hospital, Stockholm, Sweden.

Circulation
|May 25, 1999
PubMed
概括

强化胰岛素治疗显著降低了糖尿病患者急性心肌梗塞 (AMI) 的长期死亡率. 死亡率的关键预测因素包括年龄,心力衰竭史和入院葡萄糖水平,而不是传统的风险因素.

更多相关视频

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关实验视频

Last Updated: Jul 14, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

科学领域:

  • 心脏病学 心脏病学
  • 内分泌学 在内分泌学.
  • 代谢研究研究 代谢研究

背景情况:

  • 糖尿病和胰岛素葡萄糖输液在急性心肌梗塞 (DIGAMI) 研究研究了糖尿病患者经历心肌梗塞 (MI) 的预后因素和治疗效果.
  • 患有急性心肌梗塞 (AMI) 的糖尿病患者在预后因素和糖代谢控制方面面临着独特的挑战.

研究的目的:

  • 确定AMI糖尿病患者长期死亡的预后因素.
  • 评估强化胰岛素-葡萄糖输液治疗与常规抗糖尿病治疗对死亡率的影响.
  • 评估并发性治疗的作用,如血栓溶解和β-阻断剂.

主要方法:

  • 随机对照试验涉及620名患有AMI的糖尿病患者.
  • 强化胰岛素-葡萄糖输液组 (n=306) 与常规抗糖尿病治疗对照组 (n=314).
  • 统计分析 (单变量和多变量) 用于确定长期死亡率预测指标,平均随访时间为3.4年.

主要成果:

  • 长期死亡率在强化胰岛素组 (33%) 与对照组 (44%) 相比显著降低 (P=0.011).
  • 死亡率的独立预测因素包括年龄较大,先前心力衰竭,糖尿病持续时间,以及入院血糖和HbA1c水平.
  • 强化胰岛素治疗导致了代谢控制 (血糖和HbA1c) 的显著改善.

结论:

  • 患有AMI的糖尿病患者的死亡率主要由年龄,以前的心力衰竭和入院时代谢状态的严重程度预测.
  • 强化胰岛素治疗有效降低了长期死亡率,即使在高摄入葡萄糖和HbA1c水平的患者中也是如此.
  • 传统的风险因素和性别不是这个队列中死亡率的独立预测因素.